グレサチニブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
説明
Glesatinib is a TKI that targets tumors with MET and AXL alterations.
臨床応用
Nonclinical models have shown glesatinib to be effective in MET exon 14 skipping mutations. It is currently being evaluated in phase II trials in NSCLC patients with MET alterations.
グレサチニブ 上流と下流の製品情報
原材料
準備製品